CureVac (NASDAQ:CVAC) Hits New 52-Week Low at $2.54

CureVac (NASDAQ:CVAC)’s stock price hit a new 52-week low on Tuesday . The stock traded as low as $2.54 and last traded at $2.62, with a volume of 157201 shares trading hands. The stock had previously closed at $2.65.

Wall Street Analyst Weigh In

Separately, Guggenheim reaffirmed a “neutral” rating on shares of CureVac in a report on Friday, April 5th.

CureVac Stock Performance

The company has a quick ratio of 3.41, a current ratio of 3.56 and a debt-to-equity ratio of 0.06. The company’s 50 day simple moving average is $3.20 and its 200 day simple moving average is $4.32.

Hedge Funds Weigh In On CureVac

Hedge funds have recently added to or reduced their stakes in the stock. Ballentine Partners LLC purchased a new position in CureVac in the first quarter valued at approximately $38,000. China Universal Asset Management Co. Ltd. increased its stake in CureVac by 95.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,738 shares of the company’s stock valued at $39,000 after purchasing an additional 2,804 shares during the last quarter. Vontobel Holding Ltd. purchased a new position in CureVac in the fourth quarter valued at approximately $45,000. Optiver Holding B.V. increased its stake in CureVac by 2,407.0% in the third quarter. Optiver Holding B.V. now owns 6,844 shares of the company’s stock valued at $47,000 after purchasing an additional 6,571 shares during the last quarter. Finally, Pathstone Holdings LLC purchased a new position in shares of CureVac during the fourth quarter worth approximately $55,000. 17.26% of the stock is currently owned by hedge funds and other institutional investors.

About CureVac

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza.